within Pharmacolibrary.Drugs.ATC.A;

model A04AD11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.65 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,
    adminCount     = 1,
    Vd             = 0.014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0011666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Nabilone is a synthetic cannabinoid, structurally related to delta-9-tetrahydrocannabinol (THC), and acts as an agonist at the cannabinoid receptors. It is primarily used as an antiemetic in the management of nausea and vomiting associated with chemotherapy in cancer patients. Nabilone is approved for medical use in several countries, although its use is generally limited to when other antiemetics have failed.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects, following oral administration of nabilone capsules.</p><h4>References</h4><ol><li><p>McGilveray, IJ (2005). Pharmacokinetics of cannabinoids. <i>Pain research &amp; management</i> 10 Suppl A 15A–22A. DOI:<a href=&quot;https://doi.org/10.1155/2005/242516&quot;>10.1155/2005/242516</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16237477/&quot;>https://pubmed.ncbi.nlm.nih.gov/16237477</a></p></li><li><p>Davis, MP (2008). Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. <i>Expert opinion on investigational drugs</i> 17(1) 85–95. DOI:<a href=&quot;https://doi.org/10.1517/13543784.17.1.85&quot;>10.1517/13543784.17.1.85</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18095921/&quot;>https://pubmed.ncbi.nlm.nih.gov/18095921</a></p></li><li><p>Badowski, ME (2017). A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics. <i>Cancer chemotherapy and pharmacology</i> 80(3) 441–449. DOI:<a href=&quot;https://doi.org/10.1007/s00280-017-3387-5&quot;>10.1007/s00280-017-3387-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28780725/&quot;>https://pubmed.ncbi.nlm.nih.gov/28780725</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A04AD11;
